Infliximab vs Methylprednisolone for Immune-Related Diarrhea

Phase 2, randomised, open-label trial of infliximab in Immunotherapy-related colitis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Improvement in management of immune related grade 3 and 4 diarrhea as measured by proportion of responders to less than or equal to grade 1 at 78 hours and Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1 at 78 hours. Planned start Aug 2016; status: withdrawn.